The Russian Direct Investment Fund (RDIF) suggested that the American pharmaceutical company Pfizer start joint trials with “Sputnik Lite” as a booster vaccine against “Covid-19”.
“The increase in Delta cases in the US and Israel shows that messenger RNA (mRNA) vaccines need a heterogeneous booster to strengthen and prolong the immune response,” reads a tweet from the Russian Direct Investment Fund. 83.1% against the delta mutant.
“The Russian Direct Investment Fund today applied to Pfizer to begin experimenting with Sputnik Lite as a booster,” the tweet continued.
Sputnik V was the first in the world to introduce a combined trial of AstraZeneca in November 2020, co-sponsored mix-and-match trials with AstraZeneca, Moderna and Sinopharm.
According to an official statement, data collected by the Ministry of Health confirm that “Sputnik V” is still protective against newly discovered variants and maintains one of the best standards of safety and efficacy.
The Russian Ministry of Health also published data on the effectiveness of “Sputnik V” against the delta variant, and the vaccine was effective by 83.1%. The statement of the Russian Direct Investment Fund said that “Sputnik V” is 94.4 percent effective in preventing hospitalizations, with an 18-fold decrease in the risk of hospitalization.
Moreover, data obtained during mass vaccinations in Argentina, Bahrain, Hungary, Mexico, Russia, Serbia, the Philippines and the United Arab Emirates show no serious adverse effects (eg, myocarditis). In many countries where multiple vaccines are used, the Russian vaccine has been shown to be implemented with the best safety and efficacy standards.
The UAE Ministry of Health, for example, found that “Sputnik V” has an efficacy of 97.8% against “Covid-19”, with an efficacy against severe cases of 100%.
And in Hungary, the first country in the European Union to agree to “Sputnik V”, official government research showed, albeit based on a relatively small sample, that the Russian vaccine has the best safety and efficacy record of all vaccines registered by the authorities.
On the other hand, the scientific site MedRxiv published the results of a study conducted by American scientists on the effectiveness of vaccines from Moderna and Pfizer in the period from January to July 2021, during which “alpha” and “delta” strains of Corona virus infection spread in the United States.
The results revealed that both drugs showed an estimated efficacy of 86% and 76%, respectively, however, in July, against the background of the high prevalence of Delta strain, the efficacy of these vaccines decreased to 76% and 42%, respectively.
The Russian Direct Investment Fund reported that the epidemiological effectiveness of the “Sputnik V” vaccine against the Delta strain amounted to 83.1%, and the vaccine was also able to prevent the admission of infected people to hospitals in 94.3% of cases.
Besides, the director of the Research Center for Epidemiology and Microbiology explained that the “Sputnik V” vaccine is good because it forms a response to the “spike” (S) protein of the coronavirus in many combinatorial states, unlike the messenger RNA vaccines.
mRNA vaccines provide a strong immune response, but against a very limited number of antigenic variants. “Sputnik V” gives a uniform response to a very large number of antigenic variants, and this is one of its main advantages.”
Currently, Sputnik V is approved in 69 countries with a total population of over 3.7 billion people, nearly half of the world’s population.
And the fact that potions do not need to be kept in a deep freezer has made “Sputnik V” a popular choice all over the world.
The vaccine has won international praise, with leading Western scientific journals, such as The Lancet and Nature, determined that the vaccine is safe and effective against “Covid-19”.
The Russian Direct Investment Fund has concluded production partnerships with more than 20 companies in 14 countries, including leading manufacturers in India, China, South Korea, Argentina, Mexico and other countries.
The Russian Direct Investment Fund stated that the single-dose “Sputnik Lite” vaccine also shows high safety and efficacy results in Argentina, along with AstraZeneca, Sinopharm and Moderna vaccines.
Sputnik Lite is indicated as the first component of Sputnik V (recombinant human adenovirus serotype 26 (rAd26).
In particular, data from the Buenos Aires Provincial Department of Health showed that Sputnik Light helped elicit antibodies in 94% of those vaccinated and provided a robust immune response.
The Assistant Director-General of the World Health Organization, Mariangela Simao, said, Wednesday, August 11, that the “Sputnik V” vaccine could be approved by the World Health Organization by mid-September.
She added during a press conference that “Sputnik V is subject to legal procedures,” noting that the inclusion of the Russian vaccine in the COVAX mechanism developed by the World Health Organization is being considered to achieve an equal distribution of vaccines around the world.
“The dates are still uncertain to complete the process, but we expect that to happen by mid-September,” she added.
Source: RT +business standard